Metabolically Healthy Obesity Increases the Risks of MASLD and Hyperuricemia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Total Enrollment

17040 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-04-01

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Although metabolically healthy obesity (MHO) is often considered a relatively benign obesity, its association with the risk of metabolic dysfunction-associated steatotic liver disease (MASLD) and hyperuricemia remains unclear. This study examined the associations between MHO and other metabolic-obesity phenotypes with MASLD and hyperuricemia, and explored the mediating roles of metabolic indicators.This study included 11,712 and 13,846 participants from a health examination cohort at the First Affiliated Hospital of Ningbo University for MASLD and hyperuricemia analyses, respectively. Participants were classified into four metabolic-obesity phenotypes, with MHO defined as obesity without metabolic syndrome components. The outcomes were MASLD and hyperuricemia. Cox regression and mediation analyses were conducted to assess associations and mediating effects.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Prospective Cohort Study on Patient With Obesity Undergoing Weight Change

NCT07239167

Obesity & Overweight Weight Loss Metabolic Syndrome +2 more

ENROLLING_BY_INVITATION

New Non-invasive Biomarkers of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)

NCT06647095

Healthy Simple Steatosis (SS) Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) +1 more

COMPLETED

The Potential Value and Impact of Diagnostic Biomarkers for MAFLD Using Machine Learning Methods

NCT06061640

Metabolic Dysfunction-associated Fatty Liver Disease

UNKNOWN

Fatty Liver Disease Collaborative Research in China

NCT02391168

Fatty Liver Fatty Liver, Alcoholic Non-alcoholic Fatty Liver Disease

UNKNOWN

Role of New Adipokines and Hepatokines in Prediction of Patients With Metabolic Syndrome or NAFLD

NCT02285218

Non-alcoholic Fatty Liver Disease Type 2 Diabetes Metabolic Syndrome

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metabolic Dysfunction-Associated Steatotic Liver Disease Metabolically Healthy Obesity Hyperuricemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

MASLD cohort

participants with non-MASLD at baseline

No interventions assigned to this group

Hyperuricemia

participants with non-Hyperuricemia at baseline

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Underwent comprehensive health examinations at the Physical Examination Center of the First Affiliated Hospital of Ningbo University between 2017 and 2024;
2. Aged 18 years or older at baseline;
3. Completed an abdominal ultrasound examination during the health check-up.

Exclusion Criteria

1. Underweight status at baseline, defined as BMI \< 18.5 kg/m² ；
2. Missing data on height, weight, or components of the metabolic syndrome ;
3. Baseline diagnosis of MASLD or any other liver diseases
4. Baseline diagnosis of hyperuricemia

Minimum Eligible Age

18 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes